Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
2021
Abstract Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizi...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
27
References
48
Citations
NaN
KQI